Long-term efficacy and safety of once-daily nevirapine in combination with tenofovir and emtricitabine in the treatment of HIV-infected patients: a 72-week prospective multicenter study (TENOR-Trial)
<p>Abstract</p> <p>Background</p> <p>There is an unmet medical need for simplified antiretroviral therapy regimens to improve patient's compliance and quality of life. The purpose of this study was to evaluate the efficacy and safety of a once-daily regimen with Te...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2009-12-01
|
| Series: | European Journal of Medical Research |
| Subjects: | |
| Online Access: | http://www.eurjmedres.com/content/14/12/516 |
| _version_ | 1818756945256906752 |
|---|---|
| author | Weberschock T Gholam P Hueter E Flux K Hartmann M |
| author_facet | Weberschock T Gholam P Hueter E Flux K Hartmann M |
| author_sort | Weberschock T |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>There is an unmet medical need for simplified antiretroviral therapy regimens to improve patient's compliance and quality of life. The purpose of this study was to evaluate the efficacy and safety of a once-daily regimen with Tenofovir (TDF), Emtricitabine (FTC) and Nevirapine (NVP) for adult patients with HIV-1 infection.</p> <p>Methods</p> <p>70 patients were enrolled in a prospective, multicenter, non-randomized, single arm, open-label cohort study. Patients were either naïve or had problems with their current ART and needed to be changed to another regimen. Daily drug dosage was 300 mg Tenofovir, 200 mg Emtricitabine and 400 mg Nevirapine once daily. Follow-up was performed over 72 weeks.</p> <p>Results</p> <p>After 72 weeks, the regimen was still continued by 52 patients (74,3%). Of these, 44 patients (84,6%) had a viral load below detection limit. The median viral load had decreased by 2,5 log and the median CD4 cell count had increased by 44,8%. Most side-effects occurred at an early stage during the study. Resistances were rare (only two resistances were considered as newly developed) and occurred rather late during the study.</p> <p>Conclusion</p> <p>A once-daily regimen of Tenofovir, Emtricitabine and Nevirapine is an attractive treatment option since it is safe, effective, and well tolerated.</p> |
| first_indexed | 2024-12-18T06:03:06Z |
| format | Article |
| id | doaj.art-dcd3f0a1a80c45dab7e8e04c576e25c9 |
| institution | Directory Open Access Journal |
| issn | 2047-783X |
| language | English |
| last_indexed | 2024-12-18T06:03:06Z |
| publishDate | 2009-12-01 |
| publisher | BMC |
| record_format | Article |
| series | European Journal of Medical Research |
| spelling | doaj.art-dcd3f0a1a80c45dab7e8e04c576e25c92022-12-21T21:18:37ZengBMCEuropean Journal of Medical Research2047-783X2009-12-01141251610.1186/2047-783X-14-12-516Long-term efficacy and safety of once-daily nevirapine in combination with tenofovir and emtricitabine in the treatment of HIV-infected patients: a 72-week prospective multicenter study (TENOR-Trial)Weberschock TGholam PHueter EFlux KHartmann M<p>Abstract</p> <p>Background</p> <p>There is an unmet medical need for simplified antiretroviral therapy regimens to improve patient's compliance and quality of life. The purpose of this study was to evaluate the efficacy and safety of a once-daily regimen with Tenofovir (TDF), Emtricitabine (FTC) and Nevirapine (NVP) for adult patients with HIV-1 infection.</p> <p>Methods</p> <p>70 patients were enrolled in a prospective, multicenter, non-randomized, single arm, open-label cohort study. Patients were either naïve or had problems with their current ART and needed to be changed to another regimen. Daily drug dosage was 300 mg Tenofovir, 200 mg Emtricitabine and 400 mg Nevirapine once daily. Follow-up was performed over 72 weeks.</p> <p>Results</p> <p>After 72 weeks, the regimen was still continued by 52 patients (74,3%). Of these, 44 patients (84,6%) had a viral load below detection limit. The median viral load had decreased by 2,5 log and the median CD4 cell count had increased by 44,8%. Most side-effects occurred at an early stage during the study. Resistances were rare (only two resistances were considered as newly developed) and occurred rather late during the study.</p> <p>Conclusion</p> <p>A once-daily regimen of Tenofovir, Emtricitabine and Nevirapine is an attractive treatment option since it is safe, effective, and well tolerated.</p>http://www.eurjmedres.com/content/14/12/516NevirapineTenofovirEmtricitabineARTtreatment efficacyonce-daily |
| spellingShingle | Weberschock T Gholam P Hueter E Flux K Hartmann M Long-term efficacy and safety of once-daily nevirapine in combination with tenofovir and emtricitabine in the treatment of HIV-infected patients: a 72-week prospective multicenter study (TENOR-Trial) European Journal of Medical Research Nevirapine Tenofovir Emtricitabine ART treatment efficacy once-daily |
| title | Long-term efficacy and safety of once-daily nevirapine in combination with tenofovir and emtricitabine in the treatment of HIV-infected patients: a 72-week prospective multicenter study (TENOR-Trial) |
| title_full | Long-term efficacy and safety of once-daily nevirapine in combination with tenofovir and emtricitabine in the treatment of HIV-infected patients: a 72-week prospective multicenter study (TENOR-Trial) |
| title_fullStr | Long-term efficacy and safety of once-daily nevirapine in combination with tenofovir and emtricitabine in the treatment of HIV-infected patients: a 72-week prospective multicenter study (TENOR-Trial) |
| title_full_unstemmed | Long-term efficacy and safety of once-daily nevirapine in combination with tenofovir and emtricitabine in the treatment of HIV-infected patients: a 72-week prospective multicenter study (TENOR-Trial) |
| title_short | Long-term efficacy and safety of once-daily nevirapine in combination with tenofovir and emtricitabine in the treatment of HIV-infected patients: a 72-week prospective multicenter study (TENOR-Trial) |
| title_sort | long term efficacy and safety of once daily nevirapine in combination with tenofovir and emtricitabine in the treatment of hiv infected patients a 72 week prospective multicenter study tenor trial |
| topic | Nevirapine Tenofovir Emtricitabine ART treatment efficacy once-daily |
| url | http://www.eurjmedres.com/content/14/12/516 |
| work_keys_str_mv | AT weberschockt longtermefficacyandsafetyofoncedailynevirapineincombinationwithtenofovirandemtricitabineinthetreatmentofhivinfectedpatientsa72weekprospectivemulticenterstudytenortrial AT gholamp longtermefficacyandsafetyofoncedailynevirapineincombinationwithtenofovirandemtricitabineinthetreatmentofhivinfectedpatientsa72weekprospectivemulticenterstudytenortrial AT huetere longtermefficacyandsafetyofoncedailynevirapineincombinationwithtenofovirandemtricitabineinthetreatmentofhivinfectedpatientsa72weekprospectivemulticenterstudytenortrial AT fluxk longtermefficacyandsafetyofoncedailynevirapineincombinationwithtenofovirandemtricitabineinthetreatmentofhivinfectedpatientsa72weekprospectivemulticenterstudytenortrial AT hartmannm longtermefficacyandsafetyofoncedailynevirapineincombinationwithtenofovirandemtricitabineinthetreatmentofhivinfectedpatientsa72weekprospectivemulticenterstudytenortrial |